Foresite Capital Management Iii, LLC Verona Pharma PLC Transaction History

Foresite Capital Management Iii, LLC

$37.9 Million
Q3 2022

A detailed history of Foresite Capital Management Iii, LLC transactions in Verona Pharma PLC stock. As of the latest transaction made, Foresite Capital Management Iii, LLC holds 1,111,112 shares of VRNA stock, worth $74.9 Million. This represents 29.98% of its overall portfolio holdings.

Number of Shares

1,111,112

Previous 1,111,112 -0.0%

Holding current value

$74.9 Million

Previous $4.66 Million 143.9%

% of portfolio

29.98%

Previous 16.89%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2021 May 17, 2021	BUY	$7.08 - $9.33 $7.87 Million - $10.4 Million	1,111,112 New	1,111,112 $9.29 Million
Q4 2020 Feb 16, 2021	SELL	$5.51 - $8.11 $6.12 Million - $9.01 Million	-1,111,112 Closed	0 $0
Q3 2020 Nov 13, 2020	BUY	$4.45 - $10.2 $4.94 Million - $11.3 Million	1,111,112 New	1,111,112 $6.93 Million
Q1 2019 May 14, 2019	SELL	$5.52 - $10.0 $1.14 Million - $2.07 Million	-206,663 Closed	0 $0
Q4 2018 Feb 13, 2019	SELL	$9.0 - $13.47 $2.65 Million - $3.96 Million	-294,220 Reduced 58.74%	206,663 $1.99 Million
Q3 2018 Nov 13, 2018	SELL	$11.65 - $14.1 $22,624 - $27,382	-1,942 Reduced 0.39%	500,883 $6.27 Million
Q2 2018 Aug 14, 2018	SELL	$13.66 - $21.0 $853,299 - $1.31 Million	-62,467 Reduced 11.05%	502,825 $6.87 Million
Q1 2018 May 15, 2018	BUY	$11.69 - $20.97 $431,010 - $773,163	36,870 Added 6.98%	565,292 $11.3 Million
Q4 2017 Feb 13, 2018	SELL	$10.8 - $15.75 $868,633 - $1.27 Million	-80,429 Reduced 13.21%	528,422 $6.27 Million
Q3 2017 Nov 13, 2017	SELL	$11.96 - $16.95 $56,810 - $80,512	-4,750 Reduced 0.77%	608,851 $9.35 Million
Q2 2017 Aug 14, 2017	BUY	N/A	613,601	613,601 $7.15 Million

Others Institutions Holding VRNA

# of Institutions

218

Shares Held

70.5M

Call Options Held

1.4M

Put Options Held

299K

View Full List

About Verona Pharma plc

Ticker VRNA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 60,954,200
Market Cap $4.11B
Description
Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodi...

More about VRNA

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Foresite Capital Management Iii, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Foresite Capital Management Iii, LLC with notifications on news.

Account

Foresite Capital Management Iii, LLC Verona Pharma PLC Transaction History